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498 Correspondencedefinitions in peripheral endovascular re-vascularisation
trials for chronic lower limb ischaemia.1 The group did not
want to offer recommendations for the treatment itself.
The urge for this initiative was based on the observation
that often very different end-points and their definitions
were used, thus making comparison between trials diffi-
cult.2 We can hope that the guidelines, as proposed by the
DEFINE group, will lead to harmonisation and will indeed be
referred to or incorporated in future reporting of guidelines
from scientific societies such as the Society for Vascular
Surgery (SCS) and the International Society of Cardio-
Vascular Surgery (ISCVS) or Trans-Atlantic Inter-Society
Consensus (TASC).
Both letters mainly refer to the use of quality-of-life
(QOL) assessment tools in the baseline assessment and as
an outcome measure. The choice for EuroQol (EQ-5D) as the
generic measure for QOL can, as any other choice, be
disputed. It was based on its relative ease of use, its
widespread acceptance and proven validity. It is also rec-
ommended by the National Institute for Clinical Excellence
(NICE) for use in cost-utility analyses of health technolo-
gies. Its correlation with disease-specific assessment tools
in patients with intermittent claudication is, at least,
comparable to that of the 36-Item Short Form Survey
Instrument (SF-36).3
While Brees et al. may have a point in making a differ-
ence between ‘health status’ and ‘QOL’ assessment, this
difference is not generally made, and they also state in
their recent publication that ‘‘experience of genuine QOL
instruments in clinical trials is limited.’’4
Golledge et al. refer to the ‘intermittent claudication
questionnaire’ in the development of which he participated.
However, since the publication in 2002, and in contrast to the
widely usedwalking impairment questionnaire (WIQ), we did
not find a single published clinical study in which this ques-
tionnaire was used.
We believe, just as both the authors, that the inte-
gration of QOL measures is important in the set-up of
further studies and trials on endovascular re-vascular-
isation. The combination of a generic and a disease-
specific tool is recommended. For the purpose of
standardisation, based on the available evidence, their
ease of use and widespread acceptance, we opt for the
combination of EQ-5D and WIQ. We thank both authors
for their valued remarks.DOI of original article: 10.1016/j.ejvs.2008.06.023.References
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doi:10.1016/j.ejvs.2008.12.012Letter to the Editor re: Indication for Intervention in
Chronic Type B Aortic DissectionWe enjoyed reading the work by Sayer et al. which con-
tained some very interesting data.1 Of concern was that
one of the indications for intervention in chronic dissection
was the rapid growth of the aorta in excess of 1 cm in 6
months (local protocol). This is not widely accepted as
a risk for rupture which, in this group, rests solely on the
maximum aortic diameter. Rapid increase in growth was an
indication for intervention in the UK Small Aneurysm Trial,
but it is very doubtful whether it is of relevance in this
group of patients. It would be nice to know how many
patients were included in this category and what was the
absolute diameter of the aorta in each case.
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Regarding ‘‘Outcome of Endovenous Laser Therapy for
Saphenous Reflux and Varicose Veins: Medium-Term
Results Assessed by Ultrasound Surveillance’’To the editor,
We read with interest the medium-term outcomes for
patients undergoing the endovenous laser ablation (EVLA)
procedure reported by Myers and Jolley.1
A principal determinant of the success of EVLA is the
quality of energy delivered per centimetre (J cm1) of
treated vein, which acts as an indicator for fluence
(J cm2). A mathematical model by Mordon et al.2 demon-
strated that for 3-mm and 5-mm diameter veins, 65 J cm1
and 100 J cm1, respectively, are required to obtain
permanent vessel wall damage in the continuous mode.
This model harmonises with the observational study by
Theivacumar et al.,3 which found optimal long saphenous
vein ablation with 60 J cm1. Interestingly, phlebitis and
complication profile do not appear to be increased in
comparison to lower energy densities.
In the Myers and Jolley series, the median energy
delivery was 44 J cm1 (range: 16e128) and the primary
success of EVLA at 4 years was 76%. One may postulate that
primary success rates may be further improved by achieving
a median energy delivery of 60 J cm1. EVLA is stillDOI of original article: 10.1016/j.ejvs.2008.09.009.a novel technology in many centres and the technique
continues to undergo refinement. Practitioners of EVLA
should thus be encouraged to prospectively monitor their
outcomes so that the optimal technique may be elucidated.References
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